{"filing":{"accession_number":"0001171843-26-005370","cik":"0001771885","ticker":"QNTM","company_name":"Quantum Biopharma Ltd.","form":"6-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"f6k_081026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1771885/000117184326005370/f6k_081026.htm"},"events":[{"id":26324,"run_id":23916,"accession_number":"0001171843-26-005370","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces FDA approval of an Investigational New Drug (IND) application for Lucid-MS, enabling Quantum BioPharma to advance into Phase 2 clinical trials for progressive multiple sclerosis. While this is a significant regulatory milestone and clinical development advancement, it does not fit the discrete event categories of earnings_release, exec_appointment/departure, M\u0026A activity, or other named material events. The disclosure is clearly operational and strategic in nature—a major clinical/regulatory milestone that would materially affect investor assessment of the company's pipeline progress and competitive positioning in the multi-billion-dollar MS market. The company explicitly characterizes this as \"a breakthrough moment\" and \"transformative moment,\" and the CEO emphasizes it as \"an important strategic milestone.\" This is material to a reasonable investor evaluating the company's development trajectory and market opportunity.","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27407,"accession_number":"0001171843-26-005370","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of an Investigational New Drug (IND) application for Lucid-MS, enabling Quantum BioPharma to advance into Phase 2 clinical trials for progressive multiple sclerosis. While this is a significant regulatory milestone and clinical development advancement, it does not fit the discrete event categories of earnings_release, exec_appointment/departure, M\u0026A activity, or other named material events. The disclosure is clearly operational and strategic in nature—a major clinical/regulatory milestone that would materially affect investor assessment of the company's pipeline progress and competitive positioning in the multi-billion-dollar MS market. The company explicitly characterizes this as \"a breakthrough moment\" and \"transformative moment,\" and the CEO emphasizes it as \"an important strategic milestone.\" This is material to a reasonable investor evaluating the company's development trajectory and market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:01:13.768958+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27407,"accession_number":"0001171843-26-005370","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of an Investigational New Drug (IND) application for Lucid-MS, enabling Quantum BioPharma to advance into Phase 2 clinical trials for progressive multiple sclerosis. While this is a significant regulatory milestone and clinical development advancement, it does not fit the discrete event categories of earnings_release, exec_appointment/departure, M\u0026A activity, or other named material events. The disclosure is clearly operational and strategic in nature—a major clinical/regulatory milestone that would materially affect investor assessment of the company's pipeline progress and competitive positioning in the multi-billion-dollar MS market. The company explicitly characterizes this as \"a breakthrough moment\" and \"transformative moment,\" and the CEO emphasizes it as \"an important strategic milestone.\" This is material to a reasonable investor evaluating the company's development trajectory and market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:01:13.768958+00:00","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-08-10"}]}